Selective response to omalizumab in a patient with concomitant ncMCAS and POTS: what does it teach us about the underlying disease?

Kacar, M; Denman, S; Savic, S

Kacar, M; Denman, S; Savic, S.

Affiliation

Kacar, M; St James's University Hospital. Department of Clinical Immunology and Allergy. Leeds. UK
Denman, S; St James's University Hospital. Department of Clinical Immunology and Allergy. Leeds. UK
Savic, S; St James's University Hospital. Department of Clinical Immunology and Allergy. Leeds. UK

J. investig. allergol. clin. immunol ; 28(4): 261-263, 2018.

Article in English | IBECS | ID: ibc-174475

Responsible library: ES1.1

Localization: BNCS

ABSTRACT

ABSTRACT

No disponible

Subject(s)

Humans; Male; Young Adult; Mastocytosis/complications; Postural Orthostatic Tachycardia Syndrome/complications; Omalizumab/therapeutic use; Anaphylaxis/etiology; Immunologic Factors/therapeutic use; Immunoglobulins/therapeutic use; Autoimmunity/immunology

Fulltext

Add to My VHL

XML

Search on Google

Full text: Available Collection: National databases / Spain Database: IBECS Main subject: Mastocytosis / Postural Orthostatic Tachycardia Syndrome / Omalizumab Type of study: Etiology study Limits: Humans / Male Language: English Journal: J. investig. allergol. clin. immunol Year: 2018 Document type: Article Institution/Affiliation country: St James's University Hospital/UK

Fulltext

Add to My VHL

XML

Search on Google